These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 31041456)

  • 1. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
    Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
    J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early
    Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
    Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective comparison of early interim
    Su TP; Huang JS; Chang PH; Lui KW; Hsieh JC; Ng SH; Chan SC
    BMC Cancer; 2021 Aug; 21(1):908. PubMed ID: 34376155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Nielsen D; Jensen BV; Hendel HW
    J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
    Liu FY; Yen TC; Wang JY; Yang TS
    Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
    Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
    Ma B; King AD; Leung L; Wang K; Poon A; Ho WM; Mo F; Chan CML; Chan ATC; Wong SCC
    Ann Oncol; 2017 Jul; 28(7):1576-1581. PubMed ID: 28379285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
    Dhull VS; Sharma P; Sharma DN; Maharjan S; Suman Kc S; Patel C; Bal C; Kumar R
    Int J Gynecol Cancer; 2014 Feb; 24(2):312-20. PubMed ID: 24407578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
    Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
    Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.
    Nakajo M; Nakajo M; Kajiya Y; Jinguji M; Nishimata N; Shimaoka S; Nihara T; Aridome K; Tanaka S; Fukukura Y; Tani A; Koriyama C
    Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1223-32. PubMed ID: 23653240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study for texture analysis of
    Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Kitazono M; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2158-2168. PubMed ID: 28770274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of
    Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
    Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.